Novo Nordisks key drug Victoza has been backed by the European Medicines Agencys CHMP as a treatment for type 2 diabetes patients with moderate renal impairment Page 1 of 2 Click Ticker to See live coverage Novo Nordisk A/S (ADR) ( ... Bidness Etc, 1 day ago
CHMP reccommends approval of Victoza for use in adults with type 2 diabetes and moderate renal impairment - PharmaBiz, 1 day ago
Novo Nordisk's Victoza gets CHMP positive opinion to treat adults with type 2 diabetes - Pharmaceutical Business Review, 1 day ago
2 images for "Victoza"
Novo Nordisk A/S ( NVO ) announced that Victoza (once-daily) has received a positive opinion from The Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of patients suffering from type II diabetes and moderate renal ...Yahoo! Finance, 1 day ago Novo finds new way to sell Tresiba in EU while awaiting another shot in U.S. FiercePharma, 2 months ago
COPENHAGEN Nov 21 (Reuters) - Novo Nordisk A/S : ** Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment ** Once the European Commission ...Reuters UK, 4 days ago
Novo Nordisk A/S (NOVOB) , the world's largest insulin maker, reported a 1 percent gain in third-quarter profit, helped by sales of insulins and the Victoza diabetes treatment. Net income climbed to 6.5 billion kroner ($1.1 billion) from 6.42 ...Bloomberg, 3 weeks ago Novo Nordisk Forecasts 2015 Operating Profit to Rise 10% BusinessWeek, 3 weeks ago
[October 15, 2014] (Medical Marketing and Media Via Acquire Media NewsEdge) AN FDA ADVISORY panel said last month that the regula- tor should greenlight an obesity indication for Novo Nordisk's GLP-1 liraglutide, with a vote of ...TMC Net, 1 month ago
A panel of Food and Drug Administration advisors has voted to approve the use of Novo Nordisk's diabetes drug Victoza for a new indication. The panel voted 14-1 to approve the drug to be used in patients who are obese or dangerously overweight.MedIndia, 2 months ago Novo coy on Victoza weight loss filing Pharma In Focus, 2 months ago Janssen Is Working Its Way Toward Anti-Obesity Seeking Alpha, 1 week ago FDA panel backs liraglutide for obesity Drugtopics.com, 1 month ago
8% sales growth in local currencies driven by Levemir ® and Victoza ® Sales increased by 8% in local currencies and by 4% in Danish kroner to DKK 64.2 billion during the first nine months of 2014 compared to the same period in 2013. Sales of ...EuroInvestor, 3 weeks ago REG-Novo Nordisk increased operating profit in local currencies by 11% in the first nine months of 2014 Reuters, 3 weeks ago
When a new drug bursts upon an established drug class, the established players often wave away worries about market share. Sales for the whole class will grow, they say, because we'll have one more company on the street promoting it. Sometimes ...FiercePharma, 1 week ago NOVO NORDISK A/S : Why Novo's Saxenda is not Victoza 4 Traders, 1 month ago Dane in America Pharmaceutical Executive, 2 weeks ago Novo Nordisk Braves the Obesity Market Corante, 3 weeks ago
ViewPoints: Eli Lilly chooses not to compete with Victoza on list price, but discounting trends may tell a different story
You attempted to read ViewPoints , exclusive content for FirstWord Pharma PLUS members. You currently are not registered for any FirstWord Pharma services. To gain instant access to ViewPoints plus additional enhanced content and features, please ...FirstWord Pharma, 2 months ago
Novo Nordisk ($NVO) picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales. The drug pairs Tresiba, an insulin analog ...FierceBiotech, 2 months ago EU approval for Novo Nordisk's diabetes combo Pharma Field, 2 months ago
on your WebpageAdd Widget >Get your members hooked!